PLAU and breast neoplasm: The versatility of the CRISPR-dCas9 platform to upregulate PLAU expression in cells expressing low levels, while repressing expression in PLAU overexpressing cells, strengthened our conclusion on the oncogenic function of PLAU and its involvement in breast tumor aggressiveness.